Onconetix makes a test that screens for prostate cancer, approved for sale in the European Union. It is in the process of buying a company that makes humanoid robots. On September 3, the robot company announced its latest development.
Realbotix, the acquisition target, said it has launched a pilot with a European telecommunications company — which it did not name — to deploy its humanoid robots as presenters, hosts, and brand ambassadors at live events. The program tests the robots holding interactive conversations with full audiences, not just one-on-one exchanges. No dollar value was disclosed, and the partner was not identified.
Shares closed 38.02% higher at $1.0200 on September 5, on dollar volume of about $6.2 million across 18,828 trades.
Onconetix relayed the Realbotix announcement to its own shareholders on the same day it was released. According to the announcement, possible roles for the robots include corporate event hosting, live product demonstrations, education and training support, and reception and concierge functions. The pilot is also intended to test how the Realbotix platform can be configured to a partner's specific workflows, the company says.
Onconetix agreed in February 2026 to acquire 100% of Realbotix LLC, a wholly-owned subsidiary of Realbotix Corp., in an all-stock transaction. The combined company is expected to trade on Nasdaq after closing, which Onconetix says it anticipates in the second half of 2026, subject to shareholder approval, required regulatory approvals, and other conditions.
The all-stock structure means existing holders would own shares in a company that has become something quite different from the one they bought into: a humanoid robotics business rather than a cancer diagnostics one. The announcement does not say what would happen to Proclarix under the combined company.